Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancerEur. J. Cancer 2023 Jan 01;178(2023)23-33, S Loibl, D Loirat, SM Tolaney, K Punie, M Oliveira, HS Rugo, A Bardia, SA Hurvitz, AM Brufsky, K Kalinsky, J Cortés, JA O'Shaughnessy, V Dieras, LA Carey, L Gianni, M Gharaibeh, L Preger, S Phan, L Chang, L Shi, MJ Piccart
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.